Mucosis Announces Publication of Preclinical Data

Mucosis has announced the publication of preclinical data showing that FluGEM provides superior cross-protection against influenza virus.

Dutch biotechnology company Mucosis B.V. has announced the publication in the peer-reviewed journal Vaccine of preclinical data showing that FluGEM provides superior cross-protection against influenza virus.

FluGEM is a new Mimopath-based mucosal influenza vaccine that can be administered through simple droplets in the nose.

According to the report, FluGEM, a vaccine based on traditional inactivated influenza antigens formulated with bacterium-like particles (BLPs), provided full protection in mice against both homologous and heterologous influenza infection. Moreover, the results show more than 300-fold lower viral titers in the lungs when compared to conventional influenza vaccination. Reduction of viral lung titers more efficiently protects against diseas